International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship.
Issam RaadRay HachemNigo MasayukiTarcila DatoguiaHiba DagherYing JiangVivek SubbiahBilal SiddiquiArnaud BayleRobert SomerAna Fernández CruzEdward GorakArvinder BhinderNobuyoshi MoriNelson HamerschlakSamuel ShelanskiTomislav DragivichYee Elise Vong KiatSuha FakhreddinePierre Abi HannaRoy F ChemalyVictor MulanovichJavier AdachiJovan BorjanFareed KhawajaBruno GranwehrTeny JohnEduardo Yepez GuevaraHarrys TorresNatraj Reddy AmmakkanavarMarcel YibirinCielito C Reyes-GibbyMala PandeNoman AliRaniv Dawey RojoShahnoor M AliRita E DeebaPatrick ChaftariTakahiro MatsuoKazuhiro IshikawaRyo HasegawaRamón Aguado-NoyaÁlvaro García-GarcíaCristina Traseira PucholDong-Gun LeeMonica SlavinBenjamin W TehCesar A Ariasnull nullDimitrios P KontoyiannisAlexandre E MalekAnne-Marie ChaftariPublished in: medRxiv : the preprint server for health sciences (2022)
In this large multicenter worldwide study of 4015 patients with COVID-19 that included 1115 patients with cancer, we found that cancer is an independent risk factor for increased 30-day all-cause mortality. Remdesivir is a promising treatment modality to reduce 30-day all-cause mortality.